Contact
searchSearch
HMP Global

Advertisement

Advertisement

ADVERTISEMENT

Multiple Sclerosis Excellence Forum

Multiple Sclerosis
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

TNF Inhibitor Exposure May Raise Risk of Inflammatory CNS Events
Q&As
TNF Inhibitor Exposure May Raise Risk of Inflammatory CNS Events
11/13/2020
In a recent nested case-control study, researchers investigated the effects of tumor necrosis factor inhibitor exposure on the risk of inflammatory demyelinating and nondemyelinating central nervous system events. Study author Amy Kunchok,...
In a recent nested case-control study, researchers investigated the effects of tumor necrosis factor inhibitor exposure on the risk of inflammatory demyelinating and nondemyelinating central nervous system events. Study author Amy Kunchok,...
In a recent nested case-control...
11/13/2020
Neurology
Gray Matter Pathology in MS: Key Research Advances
Q&As
Gray Matter Pathology in MS: Key Research Advances
11/11/2020
At the ANA’s 145th Annual Meeting, Caterina Mainero, MD, PhD, discussed gray matter pathology in multiple sclerosis. After Dr Mainero’s presentation, Neurology Learning Network caught up with her about important research advances in this area.
At the ANA’s 145th Annual Meeting, Caterina Mainero, MD, PhD, discussed gray matter pathology in multiple sclerosis. After Dr Mainero’s presentation, Neurology Learning Network caught up with her about important research advances in this area.
At the ANA’s 145th Annual...
11/11/2020
Neurology
Autofluorescence: A Potential Biomarker for White Matter Injury in MS?
Q&As
Autofluorescence: A Potential Biomarker for White Matter Injury in MS?
11/01/2020
In a recent study, researchers investigated whether autofluorescence may serve as a marker of prior and ongoing white matter injury in chronic neurological diseases such as multiple sclerosis. Neurology Learning Network discussed the findings...
In a recent study, researchers investigated whether autofluorescence may serve as a marker of prior and ongoing white matter injury in chronic neurological diseases such as multiple sclerosis. Neurology Learning Network discussed the findings...
In a recent study, researchers...
11/01/2020
Neurology
Neuropsychiatric Disorders Among Patients With Multiple Sclerosis: Key Clinical Takeaways
Videos
Neuropsychiatric Disorders Among Patients With Multiple Sclerosis: Key Clinical Takeaways
11/01/2020
In this video, Laura T. Safar, MD, addresses the impact of neuropsychiatric disorders on quality of life among patients with multiple sclerosis, and the importance of monitoring the prevalence of depression, anxiety, and cognitive disorders...
In this video, Laura T. Safar, MD, addresses the impact of neuropsychiatric disorders on quality of life among patients with multiple sclerosis, and the importance of monitoring the prevalence of depression, anxiety, and cognitive disorders...
In this video, Laura T. Safar,...
11/01/2020
Neurology
Burcu Zeydan, MD: Important Considerations for Aging Patients With MS
Podcasts
Burcu Zeydan, MD: Important Considerations for Aging Patients With MS
10/29/2020
In this podcast, Dr Zeydan discusses how multiple sclerosis (MS) phenotypes impact the association between aging and MS, key considerations for this patient population, and more. She recently discussed this topic at the ECTRIMS/ACTRIMS...
In this podcast, Dr Zeydan discusses how multiple sclerosis (MS) phenotypes impact the association between aging and MS, key considerations for this patient population, and more. She recently discussed this topic at the ECTRIMS/ACTRIMS...
In this podcast, Dr Zeydan...
10/29/2020
Neurology
MS and COVID-19: The Pros and Cons of Telemedicine
Videos
MS and COVID-19: The Pros and Cons of Telemedicine
10/27/2020
In this video, Florian Thomas, MD, discusses the use of telemedicine among patients with multiple sclerosis during the ongoing pandemic, and what can and cannot be accomplished in a telemedicine visit.
In this video, Florian Thomas, MD, discusses the use of telemedicine among patients with multiple sclerosis during the ongoing pandemic, and what can and cannot be accomplished in a telemedicine visit.
In this video, Florian Thomas,...
10/27/2020
Neurology
MS and COVID-19: The Use of Disease-Modifying Therapies
Videos
MS and COVID-19: The Use of Disease-Modifying Therapies
10/19/2020
In this video, Florian Thomas, MD, discusses the use of disease-modifying therapies among patients with multiple sclerosis during the ongoing pandemic.
In this video, Florian Thomas, MD, discusses the use of disease-modifying therapies among patients with multiple sclerosis during the ongoing pandemic.
In this video, Florian Thomas,...
10/19/2020
Neurology
Martin Weber, MD, Discusses MOG-Mediated Disease in Multiple Sclerosis
Podcasts
Martin Weber, MD, Discusses MOG-Mediated Disease in Multiple Sclerosis
10/15/2020
In this podcast, Dr Weber discusses clinical presentations of myelin oligodendrocyte glycoprotein-mediated disease in multiple sclerosis, as well as important research developments in this field. Dr Weber recently gave a talk about...
In this podcast, Dr Weber discusses clinical presentations of myelin oligodendrocyte glycoprotein-mediated disease in multiple sclerosis, as well as important research developments in this field. Dr Weber recently gave a talk about...
In this podcast, Dr Weber...
10/15/2020
Neurology
Inflammatory Oligodendrocyte Precursor Cells and Remyelination in MS
Videos
Inflammatory Oligodendrocyte Precursor Cells and Remyelination in MS
10/06/2020
In this video, Peter Calabresi, MD, discusses the findings from his award-winning study, which suggested that inhibiting immune activation of oligodendrocyte precursor cells may foster remyelination among patients with multiple sclerosis. Dr...
In this video, Peter Calabresi, MD, discusses the findings from his award-winning study, which suggested that inhibiting immune activation of oligodendrocyte precursor cells may foster remyelination among patients with multiple sclerosis. Dr...
In this video, Peter Calabresi,...
10/06/2020
Neurology
Managing MS During the Pandemic: DMTs, Telemedicine, and More
Videos
Managing MS During the Pandemic: DMTs, Telemedicine, and More
09/30/2020
In this video, Bardia Nourbakhsh, MAS, MD, gives an overview of how COVID-19 has changed how he and his colleagues see and treat patients with multiple sclerosis in their tertiary specialty care center, and the challenges that have arisen...
In this video, Bardia Nourbakhsh, MAS, MD, gives an overview of how COVID-19 has changed how he and his colleagues see and treat patients with multiple sclerosis in their tertiary specialty care center, and the challenges that have arisen...
In this video, Bardia...
09/30/2020
Neurology

Advertisement

Advertisement

News

neurologist and patient
New Study Brief
Study Emphasizes Importance of Appropriate Application of McDonald Criteria in PPMS Diagnoses
09/15/2023
A comprehensive approach to primary progressive multiple sclerosis (PPMS) diagnosis that includes correct application of the McDonald criteria in real-world settings can improve diagnostic accuracy.
A comprehensive approach to primary progressive multiple sclerosis (PPMS) diagnosis that includes correct application of the McDonald criteria in real-world settings can improve diagnostic accuracy.
A comprehensive approach to...
09/15/2023
Neurology
Semaglutide May Lower Risk of Alzheimer Disease in Patients With Type 2 Diabetes
News
Semaglutide May Lower Risk of Alzheimer Disease in Patients With Type 2 Diabetes
11/05/2024
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Patients with type 2 diabetes...
11/05/2024
Psych Congress Network
Alone or Together, CBT and Modafinil Improve MS-Related Fatigue
News
Alone or Together, CBT and Modafinil Improve MS-Related Fatigue
11/01/2024
The wake-promoting drug modafinil, CBT, and a combination of both were associated with comparable, significant improvement in fatigue at 12 weeks in patients with MS and problematic fatigue.
The wake-promoting drug modafinil, CBT, and a combination of both were associated with comparable, significant improvement in fatigue at 12 weeks in patients with MS and problematic fatigue.
The wake-promoting drug...
11/01/2024
Neurology
Gene therapy
News
Concerns Linger After Gene Therapy Shows Long-Term Benefit for Cerebral Adrenoleukodystrophy
10/28/2024
Elivaldogene autotemcel (eli-cel) gene therapy for cerebral adrenoleukodystrophy (CALD) helped patients maintain neurological function, but also my have caused hematologic malignancies in some patients.
Elivaldogene autotemcel (eli-cel) gene therapy for cerebral adrenoleukodystrophy (CALD) helped patients maintain neurological function, but also my have caused hematologic malignancies in some patients.
Elivaldogene autotemcel...
10/28/2024
Neurology
Patient with family
News
During Recovery, Stroke Patients Benefit from Supportive Social Networks
10/24/2024
Large networks of family and friends are beneficial for blood pressure improvement among patients who experienced a stroke, according to a study published online in the International Journal of Cerebrovascular Disease and Stroke. “In aging...
Large networks of family and friends are beneficial for blood pressure improvement among patients who experienced a stroke, according to a study published online in the International Journal of Cerebrovascular Disease and Stroke. “In aging...
Large networks of family and...
10/24/2024
Neurology
International Stroke Burden Saw Hike Over Last 30 Years
News
International Stroke Burden Saw Hike Over Last 30 Years
10/22/2024
International stroke burden has increased from 1990 to 2021, according to recent findings from a global burden of disease (GBD) study published in The Lancet Neurology.
International stroke burden has increased from 1990 to 2021, according to recent findings from a global burden of disease (GBD) study published in The Lancet Neurology.
International stroke burden has...
10/22/2024
Neurology
Hands holding a head in profile with an illustrated heart over brain
News
Antiseizure Meds May Increase Cardiovascular Risk in Older Adults With Epilepsy
10/21/2024
A lifetime history of epilepsy is associated with new-onset cardiovascular events in older adults, according to study results published in JAMA Neurology.
A lifetime history of epilepsy is associated with new-onset cardiovascular events in older adults, according to study results published in JAMA Neurology.
A lifetime history of epilepsy...
10/21/2024
Neurology
FDA approval stamp
News
FDA Approves Infusion Treatment for Advanced Parkinson Disease in Adults
10/18/2024
AbbVie’s VYALEV (foscarbidopa and foslevodopa), the first 24-hour continuous subcutaneous infusion of levodopa-based therapy for managing motor fluctuations in adults with advanced Parkinson disease (PD), approved by the FDA.
AbbVie’s VYALEV (foscarbidopa and foslevodopa), the first 24-hour continuous subcutaneous infusion of levodopa-based therapy for managing motor fluctuations in adults with advanced Parkinson disease (PD), approved by the FDA.
AbbVie’s VYALEV (foscarbidopa...
10/18/2024
Neurology
Investigational Drug Improves Motor Function in Patients With SMA
News
Investigational Drug Improves Motor Function in Patients With SMA
10/16/2024
Apitegromab, an investigational muscle-targeted therapy, improved motor function in patients with spinal muscular atrophy (SMA), late-stage biopharmaceutical company Scholar Rock recently announced.
Apitegromab, an investigational muscle-targeted therapy, improved motor function in patients with spinal muscular atrophy (SMA), late-stage biopharmaceutical company Scholar Rock recently announced.
Apitegromab, an investigational...
10/16/2024
Neurology
Tolebrutinib Delays Disability Progression in Nonrelapsing Secondary Progressive MS
News
Tolebrutinib Delays Disability Progression in Nonrelapsing Secondary Progressive MS
10/15/2024
Tolebrutinib delayed the time to onset of 6-month confirmed disability progression compared with placebo in patients with nonrelapsing secondary progressive MS, according to results presented at the European Committee for Treatment and...
Tolebrutinib delayed the time to onset of 6-month confirmed disability progression compared with placebo in patients with nonrelapsing secondary progressive MS, according to results presented at the European Committee for Treatment and...
Tolebrutinib delayed the time to...
10/15/2024
Neurology
An orange prescription container with generic pills spilling out in front of it
News
Masked Taper Plus CBT for Insomnia Effective in Benzodiazepine Discontinuation
10/10/2024
A masked drug taper combined with cognitive behavioral therapy for insomnia (CBTI) were associated with improved benzodiazepine receptor agonist discontinuation in patients receiving treatment for insomnia
A masked drug taper combined with cognitive behavioral therapy for insomnia (CBTI) were associated with improved benzodiazepine receptor agonist discontinuation in patients receiving treatment for insomnia
A masked drug taper combined...
10/10/2024
Psych Congress Network

Advertisement

Advertisement

Alzheimer's Disease CME Series

Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
11/19/2020
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources To view accreditation information/faculty disclosures for the program, click 
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources To view accreditation information/faculty disclosures for the program, click 
Early Alzheimer’s Disease:...
11/19/2020
Neurology
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
11/19/2020
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesOnline Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesOnline Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease:...
11/19/2020
Neurology
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
11/19/2020
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...
Early Alzheimer’s Disease:...
11/19/2020
Neurology
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data
11/17/2020
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early...
11/17/2020
Neurology
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data
11/17/2020
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data Online Form - PBHLN-NLN Alzheimers Video Series
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data Online Form - PBHLN-NLN Alzheimers Video Series
Emerging Treatments for Early...
11/17/2020
Neurology
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data
11/17/2020
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...
Emerging Treatments for Early...
11/17/2020
Neurology
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action
11/12/2020
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early...
11/12/2020
Neurology
Early Alzheimer’s Disease Overview: Burden of Disease, Quality-of-Life Impacts, and Pathophysiology
11/12/2020
Early Alzheimer’s Disease Overview: Burden of Disease, Quality-of-Life Impacts, and Pathophysiology Online Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease Overview: Burden of Disease, Quality-of-Life Impacts, and Pathophysiology Online Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease...
11/12/2020
Neurology
Claim-Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action
11/12/2020
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...
Emerging Treatments for Early...
11/12/2020
Neurology
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease
11/10/2020
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease To view accreditation information/faculty disclosures for the program, click 
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease To view accreditation information/faculty disclosures for the program, click 
Current Treatment Limitations...
11/10/2020
Neurology

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement